Drug Trial Radar · NCT05903274
JSP191 (briquilimab) in Subjects with LR-MDS
Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
Jun 19, 2023
Primary completion
Oct 21, 2024
Study completion Oct 21, 2024
Sponsor
- Lead sponsor
- Jasper Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.
Conditions
- Lower-risk Myelodysplastic Syndrome
Interventions
JSP191Drug
Subjects will receive intravenous JSP191
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of JSP191Time frame: 32 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Memorial Healthcare System
Hollywood, Florida
Moffitt Cancer Center
Tampa, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.